In this special episode, we sit down with Shuguang Zhang, Head of the Laboratory of Molecular Architecture in the MIT Media Lab and a mentor to countless biotech explorers. His personal story has at least one literal "1 in 100 Million" moment and demonstrates the power of curiosity, kindness, and always asking questions.

We trace how Shuguang's stubbornness to pursue questions long after others give up has taken him around the world and reshaped biology. "Why is some DNA left-handed?" is a question he couldn't stop asking as a young man in China. It led him to work with one of his heroes, Alexander Rich at MIT, where he discovered zoutin (from the Chinese word for left, 左, zuo), the critical protein for mysterious Z-DNA. When he purified this new protein, he became fascinated by how it self-assembled into structures visible to the naked eye—a discovery that became PuraMatrix, now used in wound healing worldwide, and sparked generations of curiosity about self-assembling peptides.

Similarly, wondering why there are both hydrophobic and hydrophilic alpha helices led to the QTY code: a beautifully simple method to convert any membrane protein into a water-soluble form. By swapping hydrophobic residues for polar look-alikes (Q, T, and Y) without breaking geometry, this unlocks dense high-signal sensors, "molecular trap" therapeutics targeting cancer metastasis, and a fresh way to treat receptors as modular parts rather than fragile mysteries.

The pattern repeats with S-layer proteins: nature's two-dimensional crystalline lattices that orient engineered receptors 100% upright at nanometer precision. Combined with QTY-solubilized proteins, these create clean bioelectronic interfaces, ultrasensitive arrays, and new possibilities for separations and chemical monitoring.

We widen the lens to climate: industrial-scale kelp systems for carbon capture and feed, biotech routes for ocean-based materials, and practical paths to planetary solutions that borrow from biology's atomic precision and self-assembly. Kelp's exceptional photosynthetic efficiency and rapid growth make it a promising system that biotechnology could enhance through genetic engineering.

Threaded through it all are lessons from mentors like Francis Crick ("ask big questions, you get bigger answers") and Alexander Rich ("it's equally important to know what not to do"). As Shuguang puts it: "In doing science, we see a lot of things, but don't observe. To observe is to pay attention." We also talk frankly about funding setbacks, debt, persistence, and the role of AI: powerful at pattern completion, weak at original curiosity.

If you care about proteins, materials, sensors, climate biotech, or simply how a life of questioning can bend reality, this conversation is a field guide.

If the story resonates, subscribe, share with a friend, and leave a review with the one question this episode inspired you to ask next.

Read Shuguang's powerful essay "Life Has Ups and Downs, but Always Ask Questions": https://www.researchgate.net/publication/363521718_Life_Has_Ups_and_Downs_but_Always_Ask_Questions

Send us a text

Biomanufacturing doesn’t fail for lack of clever biology; it stalls at the factory gate. We sit down with Biosphere CEO Brian Heligman to unpack how a materials scientist’s journey through batteries and perovskites led to a bold thesis for the bioeconomy: change the constraints of the bioreactor and you change everything downstream. Instead of miles of steam lines and fragile commissioning, Biosphere is betting on UV-sterilized stainless systems, modern automation, and a full-stack approach that removes cost, complexity, and fear of contamination at scale.

Brian shares the hard lessons that shaped this strategy. In batteries, volumetric energy density mattered more than academic fashion. In solar, perovskite hype obscured the real blocker—stability. Translate that to biotech and the pattern holds: milligram wins and elegant papers won’t survive a plant with 50% contamination rates and $200 million capex. We walk through why legacy steam sterilization persists, how biopharma escaped into single-use plastics, and why industrial biotech needs a third path that’s cleaner, cheaper, and durable enough for daily production.

We also get tactical. What does it take to prove sterility “100 out of 100” times? How do you stress-test reactors with spore challenges, long sterile holds, and instrumentation that actually supports root-cause analysis? Why start with ag biologics (eg biostimulants and biopesticides) where customers feel the manufacturing bottleneck most acutely? And how can a 20,000-liter demonstration line bridge the gap between pilot and revenue, unlocking offtake and real unit economics without betting the company on a greenfield?

There’s a policy and resilience angle too. With defense and industrial strategy shifting toward domestic capability in vitamins, antibiotics, and specialty inputs, better reactors are not just a cost play, they’re a strategic asset. Over time, once performance is undeniable, even conservative markets like biopharma may follow. Until then, the opportunity is clear: lower the hurdle rate, reduce plastic waste, simplify scale-up, and let product companies focus on what customers actually want.

Send us a text

Pollution isn’t an abstract headline; it’s inside our bodies today. We sit down with Dr. Jenna Hua to reveal how small, everyday choices expose us to hormone-disrupting chemicals. Jenna explains why single-chemical research fails in a world of mixed exposures and shows how metabolomics turns invisible toxins into clear, personal insights you can act on now.

We trace Jenna’s path from nutrition research and a Fulbright in China to a painful fertility journey that exposed the limits of clinical testing. That lived experience powered a new model: targeted urine testing for bisphenols, phthalates, parabens, oxybenzone, and other chemicals, paired with education that helps you ditch high-exposure products and rethink packaging, takeout, and personal care. We also go behind the scenes on what it takes to make real-world science work: building shippable kits, solving messy logistics, and funding rigorous studies through SBIR grants when traditional investors wanted a simpler story.

Then we look forward. With the Healthy Nevada Project, Jenna’s team is connecting exposure profiles to genetics to understand who detoxes quickly, who bioactivates toxic intermediates, and how reducing exposure can change clinical outcomes in fertility, weight, and metabolic health. We break down targeted vs untargeted metabolomics, and why automation, AI, and product testing are the next frontier for honest labeling and safer supply chains. If you’ve wondered whether phthalate-free really means what it says, or how to make weight-loss therapy more effective by lowering obesogens, this conversation delivers science, strategy, and a roadmap you can use.

If this resonated, share it with a friend, subscribe for more climate biotech deep dives, and leave a review to help others discover the show. Your support helps bring rigorous, human-centered science to the problems that affect us all.

To learn more, check out:
Website: www.millionmarker.com (main company site)

Million Marker Research Institute: millionmarker.org (nonprofit side with white papers on product testing)

Send us a text